ArticleClinical and vaccine immunology : CVI2012
Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1.
Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 65 citations in OpenAlex.
- Microbiome-Immune Interaction and Harnessing for Next-Generation Vaccines Against Highly Pathogenic Avian Influenza in Poultry.Vaccines · 2025Review
- Oral and parenteral vaccination of broiler chickens with Recombinant NetB antigen from Clostridium perfringens confers significant protection against necrotic enteritis.BMC veterinary research · 2025Article
- Mucosal Administration ofJournal of microbiology and biotechnology · 2024Article
- An updated review on oral protein-based antigen vaccines efficiency and delivery approaches: a special attention to infectious diseases.Archives of microbiology · 2023Review
- Expression ofVaccines · 2023Article
- Recent advances in genetic tools for engineering probiotic lactic acid bacteria.Bioscience reports · 2023Article
- Evaluation the efficacy of oral immunization of broiler chickens with a recombinant Lactobacillus casei vaccine vector expressing the Carboxy-terminal fragment of α-toxin from Clostridium perfringens.BMC veterinary research · 2023Article
- Lactobacillus casei displaying Clostridium perfringens NetB antigen protects chickens against necrotic enteritis.Applied microbiology and biotechnology · 2022Article
- Anti-cancer activity of human gastrointestinal bacteria.Medical oncology (Northwood, London, England) · 2022Review
- Oral or intranasal immunization with recombinant Lactobacillus plantarum displaying head domain of Swine Influenza A virus hemagglutinin protects mice from H1N1 virus.Microbial cell factories · 2022Article
- Immune Responses Induced by RecombinantVeterinary sciences · 2022Article
- Oral Vaccination With RecombinantFrontiers in immunology · 2022Article
- The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections.Frontiers in microbiology · 2022Review
- Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.Vaccines · 2021Review
- Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus.Frontiers in pharmacology · 2021Article
- Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy.Current microbiology · 2019Review
- Immunogenicity of recombinantJournal of veterinary science · 2017Article
- Article
- Article
- Immune Responses Induced by Recombinant Bacillus Subtilis Expressing the Hemagglutinin Protein of H5N1 in chickens.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To develop a safe, effective, and convenient vaccine for the prevention of highly pathogenic avian influenza (HPAI), we have successfully constructed two recombinant lactobacillus strains (LA4356-pH and DLD17-pH) that express the foreign HPAI virus protein hemagglutinin 1 (HA(1)). The mucosal and systemic immune responses triggered by these two recombinant lactobacilli following oral administration to BALB/c mice were evaluated. The results showed that both LA4356-pH and DLD17-pH could significantly increase the specific anti-HA(1) IgA antibody level in the mucosa and the anti-HA(1) IgG level in serum, as well as stimulating the splenic lymphocyte proliferative reaction through increased expression of interleukin-4 (IL-4). Compared with LA4356-pH, DLD17-pH was more effective at inducing systemic and mucosal immune responses, with higher anti-HA(1)-specific IgA and IgG levels. Therefore, DLD17-pH could be a promising oral vaccine candidate against HPAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.